Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30-Targeted CAR-T in Lymphocyte Malignancies
NCT02958410Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD30 chimeric antigen receptor T cells in leukemia and lymphoma, sponsored by Southwest Health System. Primary endpoint: Adverse Events That Are Related to Treatment at 3 years. Status: unknown.
02
Drugs
anti-CD30 chimeric antigen receptor T cells
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NCT02958410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958410.